Cystic fibrosis (CF) is characterized by recurrent airway infections with antibiotic-resistant bacteria and chronic inflammation. Chicken cathelicin-2 (CATH-2) has been shown to exhibit antimicrobial activity against antibiotic-resistant bacteria and to reduce inflammation. In addition, exogenous pulmonary surfactant has been suggested to enhance pulmonary drug delivery. It was hypothesized that CATH-2 when combined with an exogenous surfactant delivery vehicle, bovine lipid extract surfactant (BLES), would exhibit antimicrobial activity against CF-derived bacteria and downregulate inflammation. Twelve strains of CF-pathogens were exposed to BLES+CATH-2 in vitro and killing curves were obtained to determine bactericidal activity. Secondly, heat-killed bacteria were administered in vivo to elicit a pro-inflammatory response with either a co-administration or delayed administration of BLES+CATH-2 to assess the antimicrobial-independent, anti-inflammatory properties of BLES+CATH-2. CATH-2 alone exhibited potent antimicrobial activity against all clinical strains of antibiotic-resistant bacteria, while BLES+CATH-2 demonstrated a reduction, but significant antimicrobial activity against bacterial isolates. Furthermore, BLES+CATH-2 reduced inflammation in vivo when either co-administered with killed bacteria or after delayed administration. The use of a host-defense peptide combined with an exogenous surfactant compound, BLES+CATH-2, is shown to exhibit antimicrobial activity against antibiotic-resistant CF bacterial isolates and reduce inflammation.
BackgroundBacterial pneumonia is a leading cause of death worldwide. Unfortunately, new treatments are faced with several major hurdles. Firstly, the incidence of antibiotic resistance is increasing. Secondly, both acute and chronic lung infections are often accompanied by maladaptive inflammatory responses linked to poor outcomes. Finally, the structure of the lung makes delivery of therapeutics to the sites of infection challenging. As a potential treatment for bacterial pneumonia, the current study combines a host‐defense peptide (CATH‐2), previously shown to kill antibiotic‐resistant bacteria and reduce inflammation, with an exogenous surfactant (BLES), capable of enhancing spreading throughout the lung.Objectives1) Quantify the transport CATH‐2 by BLES in vitro, 2) Assess the antimicrobial and anti‐inflammatory properties of BLES+CATH‐2 subsequent to spreading across a surface and 3) Investigate the immunomodulatory effects of BLES+CATH‐2 in vivo.HypothesisThe mixture of BLES+CATH‐2 will improve transport of CATH‐2 allowing for effective bacterial killing and reductions in inflammation at distal sites in vitro and in vivo.MethodsFluorescently‐labelled CATH‐2 was used to track its movement as it spread across a Wet Bridge Transfer system alone or in combination with BLES. Bacterial killing and anti‐inflammatory properties were assessed by seeding either a lab strain of Pseudomonas aeruginosa or RAW 264.7 macrophages to the distal well of the wet bridge system. The macrophages were stimulated with heat‐killed P. aeruginosa 15 minutes prior to the administration of saline, BLES, CATH‐2 or BLES+CATH‐2 in the proximal well. The fluid in each well was analyzed for cytokine content and bacterial killing. Additionally, a non‐infectious model of bacterial pneumonia was used, where mice were instilled with heat‐killed P. aeruginosa or saline. This first instillation was then followed by either saline, BLES, CATH‐2 or BLES+CATH‐2. All mice were monitored for 4 hours before being euthanized. Bronchoalveolar lavage fluid was collected and analyzed for cell counts, cell differentials, and cytokine concentrations.ResultsFluorescence spectrometry revealed that significantly more CATH‐2 was transferred across the bridge when combined with BLES compared to CATH‐2 by itself. Additionally, only the combination of BLES+CATH‐2 showed significant improvements in bacterial killing and reducing inflammation across the wet bridge. Mice administered heat‐killed bacteria showed significant increases in the number of inflammatory cells, neutrophils and lavage IL‐6, TNF‐α and KC content compared to saline control. Instillation of BLES+CATH‐2 after an instillation of heat‐killed bacteria showed significant reductions across all markers of inflammation compared to saline, BLES or CATH‐2 alone.DiscussionThese results support BLES as an effective vehicle for the transport of CATH‐2 and that the mixture has potent antimicrobial and anti‐inflammatory properties. Our novel approach allowed us to rapidly assess the efficacy and spreading capabilities of BLES+CATH‐2. Additionally, the results support BLES+CATH‐2 as a therapy which can overcome the delivery problem hindering pulmonary therapies and reach distal sites of inflammation.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.